Progenitor marker CD133 mRNA is elevated in peripheral blood of cancer patients with bone metastases
Progenitor marker CD133 mRNA is elevated in peripheral blood of cancer patients with bone metastases
复制标题
DOI：
10.1158/1078-0432.ccr-06-0422
复制
发表时间：
2006-08-15
影响因子：
11.5
通讯作者：
Voest, Emile E.
中科院分区：
文献类型：
--
作者：
Mehra, Niven;Penning, Maarten;Voest, Emile E.
目的：我们检测了癌症患者血液中CD 133（造血和内皮谱系祖细胞上表达的表面分子）和CD 146（泛内皮标记物）的RNA表达是否增加，以及这些因素是否与患者特征相关，是否是生存的预测因素。我们开发了一种实时定量方法（核酸序列扩增）测定131例进展性癌症患者、37例健康志愿者、5例接受粒细胞集落刺激因子治疗。获得总生存率和其他临床病理变量。结果：转移性疾病患者CD133 mRNA表达显著增加（P = 0.03），尤其是骨转移患者（P <0.001）。使用定义的截止值，与低或检测不到CD133表达的患者相比，CD133 mRNA高表达的癌症患者显示出生存率降低（20个月后累积生存率分别为21%和45%; P = 0.01）。骨转移患者的累积生存率为22%，而CD133水平高或低的患者为61%（P = 0.004）。多因素分析显示，CD133表达是骨转移患者总生存率的独立预测因子。CD146 m RNA在癌症患者中没有增加，也没有与临床变量或survival.Conclusion：CD133，而不是CD146，mRNA表达增加的癌症患者转移性疾病，特别是骨转移。此外，CD133 mRNA表达似乎是总生存率的独立预后因素。
Purpose: We examined whether RNA expression of CD133, a surface molecule expressed on progenitors from hematopoietic and endothelial lineages, and CD146, a pan-endothelial marker, are increased in the blood of cancer patients and whether these factors correlate with patient characteristics and are predictive factors of survival.Experimental Design: We developed a real-time quantification method (nuclear acid sequence-based amplification) to determine expression of CD146 and CD133 mRNA in the peripheral blood mononuclear cells of 131 progressive cancer patients, 37 healthy volunteers, and 5 patients who received granulocyte colony-stimulating factor. Overall survival and other clinicopathologic variables were obtained. Cox proportional hazards studies were done.Results: We show that patients with metastatic disease have a significant increase in CD133 mRNA (P = 0.03), specifically patients with bone metastasis (P < 0.001). Cancer patients with high CD133 mRNA expression, using a defined cutoff value, show a decreased survival compared with patients with low or undetectable CD133 expression (21% versus 45% cumulative survival, respectively, after 20 months; P = 0.01). Among patients with metastasis to the bone, cumulative survival was 22%, compared with 61% for patients with high or low CD133 levels (P = 0.004). Multivariate analysis showed that CD133 expression is an independent predictor for overall survival in patients with bone metastases. CD146 m RNA was not increased in patients with cancer, nor did it correlate with clinical variables or survival.Conclusion: CD133, but not CD146, mRNA expression is increased in cancer patients with metastatic disease, specifically with bone metastasis. In addition, CD133 mRNA expression seems to be an independent prognostic factor for overall survival.